Eligard (leuprolide; Astellas/Tolmar Pharmaceuticals) is a gonadotropin-releasing hormone (GnRH) receptor agonist which acts on the pituitary gland to stimulate luteinizing hormone (LH) release, resulting in a temporary surge in serum testosterone levels known as "flare" Persistent use of GnRH agonists over time causes downregulation of GnRH receptors in the pituitary gland, generating a significant reduction in LH and follicle-stimulating hormone secretion. This has the effect of complete shutdown of testosterone production in the testes, resulting in chemical castration.
Key Topics Covered:
List of Figures
Figure 1: Eligard sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
List of Tables
Table 1: Eligard sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/zlfqvs/2018_eligard?w=4